Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 22 entries
Sorted by: Best Match Show Resources per page
SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy.

American journal of cancer research

van der Willik KD, Timmermans MM, van Deurzen CH, Look MP, Reijm EA, van Zundert WJ, Foekens R, Trapman-Jansen AM, den Bakker MA, Westenend PJ, Martens JW, Berns EM, Jansen MP.
PMID: 27186402
Am J Cancer Res. 2016 Jan 15;6(2):270-84. eCollection 2016.

Our previous study demonstrated that high mRNA levels for Seven in Absentia Homolog 2 (SIAH2) correlated with high Estrogen Receptor (ER) mRNA levels and with longer progression-free survival (PFS) after first-line tamoxifen. Others showed high SIAH2 protein levels in...

Cite
van der Willik KD, Timmermans MM, van Deurzen CH, et al. SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy. Am J Cancer Res. 2016;6(2):270-84
van der Willik, K. D., Timmermans, M. M., van Deurzen, C. H., Look, M. P., Reijm, E. A., van Zundert, W. J., Foekens, R., Trapman-Jansen, A. M., den Bakker, M. A., Westenend, P. J., Martens, J. W., Berns, E. M., & Jansen, M. P. (2016). SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy. American journal of cancer research, 6(2), 270-84.
van der Willik, Kimberly D, et al. "SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy." American journal of cancer research vol. 6,2 (2016): 270-84.
van der Willik KD, Timmermans MM, van Deurzen CH, Look MP, Reijm EA, van Zundert WJ, Foekens R, Trapman-Jansen AM, den Bakker MA, Westenend PJ, Martens JW, Berns EM, Jansen MP. SIAH2 protein expression in breast cancer is inversely related with ER status and outcome to tamoxifen therapy. Am J Cancer Res. 2016 Jan 15;6(2):270-84. eCollection 2016. PMID: 27186402; PMCID: PMC4859659.
Copy Download .nbib Format: NLM
Understanding drugs in breast cancer through drug sensitivity screening.

SpringerPlus

Uhr K, Prager-van der Smissen WJ, Heine AA, Ozturk B, Smid M, Göhlmann HW, Jager A, Foekens JA, Martens JW.
PMID: 26543746
Springerplus. 2015 Oct 15;4:611. doi: 10.1186/s40064-015-1406-8. eCollection 2015.

With substantial numbers of breast tumors showing or acquiring treatment resistance, it is of utmost importance to develop new agents for the treatment of the disease, to know their effectiveness against breast cancer and to understand their relationships with...

Cite
Uhr K, Prager-van der Smissen WJ, Heine AA, et al. Understanding drugs in breast cancer through drug sensitivity screening. Springerplus. 2015;4:611doi: 10.1186/s40064-015-1406-8.
Uhr, K., Prager-van der Smissen, W. J., Heine, A. A., Ozturk, B., Smid, M., Göhlmann, H. W., Jager, A., Foekens, J. A., & Martens, J. W. (2015). Understanding drugs in breast cancer through drug sensitivity screening. SpringerPlus, 4611. https://doi.org/10.1186/s40064-015-1406-8
Uhr, Katharina, et al. "Understanding drugs in breast cancer through drug sensitivity screening." SpringerPlus vol. 4 (2015): 611. doi: https://doi.org/10.1186/s40064-015-1406-8
Uhr K, Prager-van der Smissen WJ, Heine AA, Ozturk B, Smid M, Göhlmann HW, Jager A, Foekens JA, Martens JW. Understanding drugs in breast cancer through drug sensitivity screening. Springerplus. 2015 Oct 15;4:611. doi: 10.1186/s40064-015-1406-8. eCollection 2015. PMID: 26543746; PMCID: PMC4628005.
Copy Download .nbib Format: NLM
Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers.

Cancers

Weerts MJA, Smid M, Foekens JA, Sleijfer S, Martens JWM.
PMID: 30544876
Cancers (Basel). 2018 Dec 09;10(12). doi: 10.3390/cancers10120500.

The human mitochondrial DNA (mtDNA) encodes 37 genes, including thirteen proteins essential for the respiratory chain, and RNAs functioning in the mitochondrial translation apparatus. The total number of mtDNA molecules per cell (mtDNA content) is variable between tissue types...

Cite
Weerts MJA, Smid M, Foekens JA, et al. Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers. Cancers (Basel). 2018;10(12)doi: 10.3390/cancers10120500.
Weerts, M. J. A., Smid, M., Foekens, J. A., Sleijfer, S., & Martens, J. W. M. (2018). Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers. Cancers, 10(12), . https://doi.org/10.3390/cancers10120500
Weerts, Marjolein J A, et al. "Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers." Cancers vol. 10,12 (2018). doi: https://doi.org/10.3390/cancers10120500
Weerts MJA, Smid M, Foekens JA, Sleijfer S, Martens JWM. Mitochondrial RNA Expression and Single Nucleotide Variants in Association with Clinical Parameters in Primary Breast Cancers. Cancers (Basel). 2018 Dec 09;10(12). doi: 10.3390/cancers10120500. PMID: 30544876; PMCID: PMC6318759.
Copy Download .nbib Format: NLM
Loss of Y-Chromosome during Male Breast Carcinogenesis.

Cancers

Agahozo MC, Timmermans MAM, Sleddens HFBM, Foekens R, Trapman-Jansen AMAC, Schröder CP, van Leeuwen-Stok E, Martens JWM, N M Dinjens W, van Deurzen CHM.
PMID: 32182822
Cancers (Basel). 2020 Mar 09;12(3). doi: 10.3390/cancers12030631.

Loss of Y-chromosome (LOY) is associated with increased cancer mortality in males. The prevalence of LOY in male breast cancer (BC) is unknown. The aim of this study is to assess the presence and prognostic effect of LOY during...

Cite
Agahozo MC, Timmermans MAM, Sleddens HFBM, et al. Loss of Y-Chromosome during Male Breast Carcinogenesis. Cancers (Basel). 2020;12(3)doi: 10.3390/cancers12030631.
Agahozo, M. C., Timmermans, M. A. M., Sleddens, H. F. B. M., Foekens, R., Trapman-Jansen, A. M. A. C., Schröder, C. P., van Leeuwen-Stok, E., Martens, J. W. M., N M Dinjens, W., & van Deurzen, C. H. M. (2020). Loss of Y-Chromosome during Male Breast Carcinogenesis. Cancers, 12(3), . https://doi.org/10.3390/cancers12030631
Agahozo, Marie Colombe, et al. "Loss of Y-Chromosome during Male Breast Carcinogenesis." Cancers vol. 12,3 (2020). doi: https://doi.org/10.3390/cancers12030631
Agahozo MC, Timmermans MAM, Sleddens HFBM, Foekens R, Trapman-Jansen AMAC, Schröder CP, van Leeuwen-Stok E, Martens JWM, N M Dinjens W, van Deurzen CHM. Loss of Y-Chromosome during Male Breast Carcinogenesis. Cancers (Basel). 2020 Mar 09;12(3). doi: 10.3390/cancers12030631. PMID: 32182822; PMCID: PMC7139680.
Copy Download .nbib Format: NLM
Ethical considerations for health professions education research matter.

Journal of professional nursing : official journal of the American Association of Colleges of Nursing

Schutte T, Fokkens J, Bertens R, Scherpbier A.
PMID: 34887044
J Prof Nurs. 2021 Nov-Dec;37(6):1205-1206. doi: 10.1016/j.profnurs.2021.08.005. Epub 2021 Aug 06.

No abstract available.

Cite
Schutte T, Fokkens J, Bertens R, et al. Ethical considerations for health professions education research matter. J Prof Nurs. 2021;37(6):1205-1206doi: 10.1016/j.profnurs.2021.08.005.
Schutte, T., Fokkens, J., Bertens, R., & Scherpbier, A. (2021). Ethical considerations for health professions education research matter. Journal of professional nursing : official journal of the American Association of Colleges of Nursing, 37(6), 1205-1206. https://doi.org/10.1016/j.profnurs.2021.08.005
Schutte, Tim, et al. "Ethical considerations for health professions education research matter." Journal of professional nursing : official journal of the American Association of Colleges of Nursing vol. 37,6 (2021): 1205-1206. doi: https://doi.org/10.1016/j.profnurs.2021.08.005
Schutte T, Fokkens J, Bertens R, Scherpbier A. Ethical considerations for health professions education research matter. J Prof Nurs. 2021 Nov-Dec;37(6):1205-1206. doi: 10.1016/j.profnurs.2021.08.005. Epub 2021 Aug 06. PMID: 34887044.
Copy Download .nbib Format: NLM
What Matters to Patients with Rheumatoid Arthritis When Facing Medical or Non-Medical Treatment Decisions?.

Patient preference and adherence

Cornelissen LE, van der Mark EJ, Pennings P, Maat B, Foekens T, Willemsen-de Mey G, Voogdt-Pruis HR.
PMID: 34465982
Patient Prefer Adherence. 2021 Aug 24;15:1827-1841. doi: 10.2147/PPA.S322257. eCollection 2021.

BACKGROUND: In rheumatoid arthritis care, patients and healthcare professionals regularly face health treatment decisions. Sorting out what matters to a patient as being relevant to a specific decision is therefore essential.METHODS: An explorative mixed-methods study was performed to investigate...

Cite
Cornelissen LE, van der Mark EJ, Pennings P, et al. What Matters to Patients with Rheumatoid Arthritis When Facing Medical or Non-Medical Treatment Decisions?. Patient Prefer Adherence. 2021;15:1827-1841doi: 10.2147/PPA.S322257.
Cornelissen, L. E., van der Mark, E. J., Pennings, P., Maat, B., Foekens, T., Willemsen-de Mey, G., & Voogdt-Pruis, H. R. (2021). What Matters to Patients with Rheumatoid Arthritis When Facing Medical or Non-Medical Treatment Decisions?. Patient preference and adherence, 151827-1841. https://doi.org/10.2147/PPA.S322257
Cornelissen, Lisa Emily, et al. "What Matters to Patients with Rheumatoid Arthritis When Facing Medical or Non-Medical Treatment Decisions?." Patient preference and adherence vol. 15 (2021): 1827-1841. doi: https://doi.org/10.2147/PPA.S322257
Cornelissen LE, van der Mark EJ, Pennings P, Maat B, Foekens T, Willemsen-de Mey G, Voogdt-Pruis HR. What Matters to Patients with Rheumatoid Arthritis When Facing Medical or Non-Medical Treatment Decisions?. Patient Prefer Adherence. 2021 Aug 24;15:1827-1841. doi: 10.2147/PPA.S322257. eCollection 2021. PMID: 34465982; PMCID: PMC8403072.
Copy Download .nbib Format: NLM
The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome.

Cancers

de Kruijff IE, Timmermans AM, den Bakker MA, Trapman-Jansen AMAC, Foekens R, Meijer-Van Gelder ME, Oomen-de Hoop E, Smid M, Hollestelle A, van Deurzen CHM, Foekens JA, Martens JWM, Sleijfer S.
PMID: 29734758
Cancers (Basel). 2018 May 05;10(5). doi: 10.3390/cancers10050134.

CD146, involved in epithelial-to-mesenchymal transition (EMT), might affect cancer aggressiveness. We here investigated the prevalence of CD146 expression in breast cancer subtypes, its relation to prognosis, the relation between CD146 and EMT and the outcome to tamoxifen. Primary breast...

Cite
de Kruijff IE, Timmermans AM, den Bakker MA, et al. The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome. Cancers (Basel). 2018;10(5)doi: 10.3390/cancers10050134.
de Kruijff, I. E., Timmermans, A. M., den Bakker, M. A., Trapman-Jansen, A. M. A. C., Foekens, R., Meijer-Van Gelder, M. E., Oomen-de Hoop, E., Smid, M., Hollestelle, A., van Deurzen, C. H. M., Foekens, J. A., Martens, J. W. M., & Sleijfer, S. (2018). The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome. Cancers, 10(5), . https://doi.org/10.3390/cancers10050134
de Kruijff, Ingeborg E, et al. "The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome." Cancers vol. 10,5 (2018). doi: https://doi.org/10.3390/cancers10050134
de Kruijff IE, Timmermans AM, den Bakker MA, Trapman-Jansen AMAC, Foekens R, Meijer-Van Gelder ME, Oomen-de Hoop E, Smid M, Hollestelle A, van Deurzen CHM, Foekens JA, Martens JWM, Sleijfer S. The Prevalence of CD146 Expression in Breast Cancer Subtypes and Its Relation to Outcome. Cancers (Basel). 2018 May 05;10(5). doi: 10.3390/cancers10050134. PMID: 29734758; PMCID: PMC5977107.
Copy Download .nbib Format: NLM
Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nature

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, Van't Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.
PMID: 30659290
Nature. 2019 Feb;566(7742):E1. doi: 10.1038/s41586-019-0883-2.

In the Methods section of this Article, 'greater than' should have been 'less than' in the sentence 'Putative regions of clustered rearrangements were identified as having an average inter-rearrangement distance that was at least 10 times greater than the...

Cite
Nik-Zainal S, Davies H, Staaf J, et al. Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2019;566(7742):E1doi: 10.1038/s41586-019-0883-2.
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., Van Loo, P., Ju, Y. S., Smid, M., Brinkman, A. B., Morganella, S., Aure, M. R., Lingjærde, O. C., Langerød, A., Ringnér, M., Ahn, S. M., Boyault, S., Brock, J. E., Broeks, A., Butler, A., Desmedt, C., Dirix, L., Dronov, S., Fatima, A., Foekens, J. A., Gerstung, M., Hooijer, G. K. J., Jang, S. J., Jones, D. R., Kim, H. Y., King, T. A., Krishnamurthy, S., Lee, H. J., Lee, J. Y., Li, Y., McLaren, S., Menzies, A., Mustonen, V., O'Meara, S., Pauporté, I., Pivot, X., Purdie, C. A., Raine, K., Ramakrishnan, K., Rodríguez-González, F. G., Romieu, G., Sieuwerts, A. M., Simpson, P. T., Shepherd, R., Stebbings, L., Stefansson, O. A., Teague, J., Tommasi, S., Treilleux, I., Van den Eynden, G. G., Vermeulen, P., Vincent-Salomon, A., Yates, L., Caldas, C., Van't Veer, L., Tutt, A., Knappskog, S., Tan, B. K. T., Jonkers, J., Borg, �. �., Ueno, N. T., Sotiriou, C., Viari, A., Futreal, P. A., Campbell, P. J., Span, P. N., Van Laere, S., Lakhani, S. R., Eyfjord, J. E., Thompson, A. M., Birney, E., Stunnenberg, H. G., van de Vijver, M. J., Martens, J. W. M., Børresen-Dale, A. L., Richardson, A. L., Kong, G., Thomas, G., & Stratton, M. R. (2019). Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature, 566(7742), E1. https://doi.org/10.1038/s41586-019-0883-2
Nik-Zainal, Serena, et al. "Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences." Nature vol. 566,7742 (2019): E1. doi: https://doi.org/10.1038/s41586-019-0883-2
Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, Van't Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR. Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature. 2019 Feb;566(7742):E1. doi: 10.1038/s41586-019-0883-2. PMID: 30659290.
Copy Download .nbib Format: NLM
Global proteomic characterization of microdissected estrogen receptor positive breast tumors.

Data in brief

De Marchi T, Liu NQ, Sting C, Smid M, Tjoa M, Braakman RB, Luider TM, Foekens JA, Martens JW, Umar A.
PMID: 26958599
Data Brief. 2015 Oct 08;5:399-402. doi: 10.1016/j.dib.2015.09.034. eCollection 2015 Dec.

We here describe two proteomic datasets deposited in ProteomeXchange via PRIDE partner repository [1] with dataset identifiers PXD000484 (defined as "training") and PXD000485 (defined as "test") that have been used for the development of a tamoxifen outcome predictive signature...

Cite
De Marchi T, Liu NQ, Sting C, et al. Global proteomic characterization of microdissected estrogen receptor positive breast tumors. Data Brief. 2015;5:399-402doi: 10.1016/j.dib.2015.09.034.
De Marchi, T., Liu, N. Q., Sting, C., Smid, M., Tjoa, M., Braakman, R. B., Luider, T. M., Foekens, J. A., Martens, J. W., & Umar, A. (2015). Global proteomic characterization of microdissected estrogen receptor positive breast tumors. Data in brief, 5399-402. https://doi.org/10.1016/j.dib.2015.09.034
De Marchi, Tommaso, et al. "Global proteomic characterization of microdissected estrogen receptor positive breast tumors." Data in brief vol. 5 (2015): 399-402. doi: https://doi.org/10.1016/j.dib.2015.09.034
De Marchi T, Liu NQ, Sting C, Smid M, Tjoa M, Braakman RB, Luider TM, Foekens JA, Martens JW, Umar A. Global proteomic characterization of microdissected estrogen receptor positive breast tumors. Data Brief. 2015 Oct 08;5:399-402. doi: 10.1016/j.dib.2015.09.034. eCollection 2015 Dec. PMID: 26958599; PMCID: PMC4773412.
Copy Download .nbib Format: NLM
Drug release from suppositories.

Pharmaceutical research

de Blaey CJ, Fokkens JG.
PMID: 24272609
Pharm Res. 1985 Mar;2(2):61-4. doi: 10.1023/A:1016330409508.

Many studies have been carried out over the past decades on suppositories and their drug release properties. The present state of knowledge is reviewed with the conclusion that our current understanding of the in vivo performance of suppositories is...

Cite
de Blaey CJ, Fokkens JG. Drug release from suppositories. Pharm Res. 1985;2(2):61-4doi: 10.1023/A:1016330409508.
de Blaey, C. J., & Fokkens, J. G. (1985). Drug release from suppositories. Pharmaceutical research, 2(2), 61-4. https://doi.org/10.1023/A:1016330409508
de Blaey, C J, and Fokkens, J G. "Drug release from suppositories." Pharmaceutical research vol. 2,2 (1985): 61-4. doi: https://doi.org/10.1023/A:1016330409508
de Blaey CJ, Fokkens JG. Drug release from suppositories. Pharm Res. 1985 Mar;2(2):61-4. doi: 10.1023/A:1016330409508. PMID: 24272609.
Copy Download .nbib Format: NLM
Ethical considerations for health professions education research matter.

Journal of professional nursing : official journal of the American Association of Colleges of Nursing

Schutte T, Fokkens J, Bertens R, Scherpbier A.
PMID: 34887044
J Prof Nurs. 2021 Nov-Dec;37(6):1205-1206. doi: 10.1016/j.profnurs.2021.08.005. Epub 2021 Aug 06.

No abstract available.

Cite
Schutte T, Fokkens J, Bertens R, et al. Ethical considerations for health professions education research matter. J Prof Nurs. 2021;37(6):1205-1206doi: 10.1016/j.profnurs.2021.08.005.
Schutte, T., Fokkens, J., Bertens, R., & Scherpbier, A. (2021). Ethical considerations for health professions education research matter. Journal of professional nursing : official journal of the American Association of Colleges of Nursing, 37(6), 1205-1206. https://doi.org/10.1016/j.profnurs.2021.08.005
Schutte, Tim, et al. "Ethical considerations for health professions education research matter." Journal of professional nursing : official journal of the American Association of Colleges of Nursing vol. 37,6 (2021): 1205-1206. doi: https://doi.org/10.1016/j.profnurs.2021.08.005
Schutte T, Fokkens J, Bertens R, Scherpbier A. Ethical considerations for health professions education research matter. J Prof Nurs. 2021 Nov-Dec;37(6):1205-1206. doi: 10.1016/j.profnurs.2021.08.005. Epub 2021 Aug 06. PMID: 34887044.
Copy Download .nbib Format: NLM
Genome-wide DNA methylation profiling of non-small cell lung carcinomas.

Epigenetics & chromatin

Carvalho RH, Haberle V, Hou J, van Gent T, Thongjuea S, van Ijcken W, Kockx C, Brouwer R, Rijkers E, Sieuwerts A, Foekens J, van Vroonhoven M, Aerts J, Grosveld F, Lenhard B, Philipsen S.
PMID: 22726460
Epigenetics Chromatin. 2012 Jun 22;5(1):9. doi: 10.1186/1756-8935-5-9.

BACKGROUND: Non-small cell lung carcinoma (NSCLC) is a complex malignancy that owing to its heterogeneity and poor prognosis poses many challenges to diagnosis, prognosis and patient treatment. DNA methylation is an important mechanism of epigenetic regulation involved in normal...

Cite
Carvalho RH, Haberle V, Hou J, et al. Genome-wide DNA methylation profiling of non-small cell lung carcinomas. Epigenetics Chromatin. 2012;5(1):9doi: 10.1186/1756-8935-5-9.
Carvalho, R. H., Haberle, V., Hou, J., van Gent, T., Thongjuea, S., van Ijcken, W., Kockx, C., Brouwer, R., Rijkers, E., Sieuwerts, A., Foekens, J., van Vroonhoven, M., Aerts, J., Grosveld, F., Lenhard, B., & Philipsen, S. (2012). Genome-wide DNA methylation profiling of non-small cell lung carcinomas. Epigenetics & chromatin, 5(1), 9. https://doi.org/10.1186/1756-8935-5-9
Carvalho, Rejane Hughes, et al. "Genome-wide DNA methylation profiling of non-small cell lung carcinomas." Epigenetics & chromatin vol. 5,1 (2012): 9. doi: https://doi.org/10.1186/1756-8935-5-9
Carvalho RH, Haberle V, Hou J, van Gent T, Thongjuea S, van Ijcken W, Kockx C, Brouwer R, Rijkers E, Sieuwerts A, Foekens J, van Vroonhoven M, Aerts J, Grosveld F, Lenhard B, Philipsen S. Genome-wide DNA methylation profiling of non-small cell lung carcinomas. Epigenetics Chromatin. 2012 Jun 22;5(1):9. doi: 10.1186/1756-8935-5-9. PMID: 22726460; PMCID: PMC3407794.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 22 entries